Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus

Journal of Diabetes and its Complications

Volumn 30, Issue 4, 2016, Pages 686-692

  Quan, Huibiao ^a   Zhang, Huachuan ^a   Wei, Weiping ^a   Fang, Tuanyu ^a  

^a HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Combination therapy; Exenatide; Gender difference; Metformin; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY MASS; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENDER; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; HYPERGLYCEMIA; METABOLISM; OVERWEIGHT; RANDOMIZED CONTROLLED TRIAL; SEXUAL DEVELOPMENT; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; PEPTIDES; SEX CHARACTERISTICS; VENOMS; WEIGHT LOSS;

EID: 84957916326     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.01.013     Document Type: Article

References (33)

1. M.A. Abdul-Ghani, C. Puckett, C. Triplitt, D. Maggs, J. Adams, E. Cersosimo, and R.A. De-Fronzo Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial Diabetes, Obesity & Metabolism 17 2015 268 275
2. American Diabetes A Standards of medical care in diabetes - 2009 Diabetes Care 32 Suppl. 1 2009 S13 S61
3. L. Blonde, R. Pencek, and L. MacConell Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes Cardiovascular Diabetology 14 2015 12 21
4. E. Carmona-Montesinos, Z. Ruiz-Fragoso, G. Ponce-Hinojosa, and S. Rivas-Arancibia Changes in C-reactive protein and biochemical profile in preschool children with obesity Nutrición Hospitalaria 32 2015 1548 1553
5. R. Chatterjee, K.V. Narayan, J. Lipscomb, S.L. Jackson, Q. Long, M. Zhu, and L.S. Phillips Screening for diabetes and prediabetes should be cost-saving in patients at high risk Diabetes Care 36 2013 1981 1987
6. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
7. G. Derosa, I.G. Franzetti, F. Querci, A. Carbone, L. Ciccarelli, and M.N. Piccinni P. Maffioli Exenatide plus metformin compared with metformin alone on beta-cell function in patients with type 2 diabetes Diabetic Medicine: a Journal of the British Diabetic Association 29 2012 1515 1523
8. D.J. Freeman, J. Norrie, M.J. Caslake, A. Gaw, I. Ford, and G.D. Lowe N. Sattar C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study Diabetes 51 2002 1596 1600
9. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clinical Chemistry 18 1972 499 502
10. A.J. Garber, T.G. Duncan, A.M. Goodman, D.J. Mills, and J.L. Rohlf Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial The American Journal of Medicine 103 1997 491 497
11. General Assembly of the World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects The Journal of the American College of Dentists 81 2014 14 18
12. F.J. Gomez-Perez, C.A. Aguilar-Salinas, P. Almeda-Valdes, D. Cuevas-Ramos, I. Lerman Garber, and J.A. Rull HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article Archives of Medical Research 41 2010 302 308
13. K.M. Heppner, and D. Perez-Tilve GLP-1 based therapeutics: simultaneously combating T2DM and obesity Frontiers in Neuroscience 9 2015 92 102
14. A.M. Heraclides, T. Chandola, D.R. Witte, and E.J. Brunner Work stress, obesity and the risk of type 2 diabetes: gender-specific bidirectional effect in the Whitehall II study Obesity (Silver Spring) 20 2012 428 433
15. G. Horigan, K. McGuigan, L. Quinn, and V. Coates Does gender make a difference to self-management of diabetes in adults ≤ 55 years? A pilot study Diabetes Medicine 32 2015 140 148
16. G.S. Hotamisligil, P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance The Journal of Clinical Investigation 95 1995 2409 2415
17. K. Hotta, T. Funahashi, N.L. Bodkin, H.K. Ortmeyer, Y. Arita, B.C. Hansen, and Y. Matsuzawa Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys Diabetes 50 2001 1126 1133
18. S.W. Kim Triple combination therapy using metformin, thiazolidinedione, and a GLP-1 analog or DPP-IV inhibitor in patients with type 2 diabetes mellitus Korean diabetes journal 34 2010 331 337
19. J. Koska, M. Sands, C. Burciu, K.M. D'Souza, K. Raravikar, and J. Liu P.D. Reaven Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans Diabetes 64 2015 2624 2635
20. C.P. Lewis, and J.N. Newell Patients' perspectives of care for type 2 diabetes in Bangladesh - a qualitative study BMC Public Health 14 2014 737
21. Y. Matsuzawa Adiponectin: a key player in obesity related disorders Current Pharmaceutical Design 16 2010 1896 1901
22. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature Reviews Endocrinology 8 2012 728 742
23. J.L. Moreno, K.C. Willett, and A.R. Desilets Exenatide as a novel weight loss modality in patients without diabetes The Annals of Pharmacotherapy 46 2012 1700 1706
24. D. Mozaffarian, T. Hao, E.B. Rimm, W.C. Willett, and F.B. Hu Changes in diet and lifestyle and long-term weight gain in women and men The New England Journal of Medicine 364 2011 2392 2404
25. N. Pond, N. Sturock, and W. Jeffcoate Age related changes in glycosylated haemoglobin in patients with IDDM Diabetic Medicine 13 1996 510 513
26. 2): a prospective controlled study Obesity Surgery 21 2011 880 888
27. A. Shehzad, W. Iqbal, O. Shehzad, and Y.S. Lee Adiponectin: regulation of its production and its role in human diseases Hormones 11 2012 8 20
28. A.K. Singh, S. Tiwari, A. Gupta, K.K. Shukla, K.G. Chhabra, A. Pandey, and A.B. Pant Association of resistin with insulin resistance and factors of metabolic syndrome in North Indians Indian Journal of Clinical Biochemistry: IJCB 30 2015 255 262
29. C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, and C.M. Wright M.A. Lazar The hormone resistin links obesity to diabetes Nature 409 2001 307 312
30. C.M. Steppan, and M.A. Lazar Resistin and obesity-associated insulin resistance Trends in endocrinology and metabolism: TEM 13 2002 18 23
31. S. Thanakun, and Y. Izumi Effect of periodontitis on adiponectin, C-reactive protein and immunoglobulin G to Porphyromonas gingivalis in overweight or obese Thai people Journal of Periodontology 2015 1 16
32. X.F. Wang, J.J. Liu, J. Xia, J. Liu, V. Mirabella, and Z.P. Pang Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons Cell Reports 12 2015 726 733
33. S. Wannamethee, O. Papacosta, D. Lawlor, P. Whincup, G. Lowe, S. Ebrahim, and N. Sattar Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study Diabetologia 55 2012 80 87.